EU steps forward in adoption of Nagoya Protocol on genetic resources
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has welcomed the European Parliament resolution on the conclusion by the European Union of the Nagoya Protocol, as well as the adoption of the EU Regulation on Access to Genetic Resources and the fair and equitable sharing of benefits arising from their utilization.
These are a step forward in the long process towards implementation of the Nagoya Protocol, which will only enter into force after 50 countries have ratified it. The EU’s ratification is the 30th but will certainly give a major boost to the international effort.
The EFPIA supports the objectives of the Convention on Biological Diversity (CBD) and the Nagoya Protocol and welcomes the successful resolution by EU policy-makers of the complex discussions on access and fair benefit sharing.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze